234 related articles for article (PubMed ID: 4905153)
1. Toxicity of E. coli L-asparaginase in man.
Oettgen HF; Stephenson PA; Schwartz MK; Leeper RD; Tallai L; Tan CC; Clarkson BD; Golbey RB; Krakoff IH; Karnofsky DA; Murphy ML; Burchenal JH
Cancer; 1970 Feb; 25(2):253-78. PubMed ID: 4905153
[No Abstract] [Full Text] [Related]
2. E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children.
Tallal L; Tan C; Oettgen H; Wollner N; McCarthy M; Helson L; Burchenal J; Karnofsky D; Murphy ML
Cancer; 1970 Feb; 25(2):306-20. PubMed ID: 4905155
[No Abstract] [Full Text] [Related]
3. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease.
Haskell CM; Canellos GP; Leventhal BG; Carbone PP; Block JB; Serpick AA; Selawry OS
N Engl J Med; 1969 Nov; 281(19):1028-34. PubMed ID: 4898857
[No Abstract] [Full Text] [Related]
4. Clinical experience with L-asparaginase.
Carbone PP; Haskell CM; Leventhal BG; Block JB; Selawry OS
Recent Results Cancer Res; 1970; 33():236-43. PubMed ID: 4949163
[No Abstract] [Full Text] [Related]
5. Clinical evaluation of L-asparaginase. Introduction.
Burchenal JH; Karnofsky DA
Cancer; 1970 Feb; 25(2):241-3. PubMed ID: 4905151
[No Abstract] [Full Text] [Related]
6. Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors.
Clarkson B; Krakoff I; Burchenal J; Karnofsky D; Golbey R; Dowling M; Oettgen H; Lipton A
Cancer; 1970 Feb; 25(2):279-305. PubMed ID: 4905154
[No Abstract] [Full Text] [Related]
7. Dysmetabolic and neurological complications in leukemia patients treated with L-asparaginase.
Storti E; Quaglino D
Recent Results Cancer Res; 1970; 33():344-9. PubMed ID: 5292723
[No Abstract] [Full Text] [Related]
8. Comparison of daily versus weekly L-asparaginase for the treatment of childhood acute leukemia.
Pratt CB; Simone JV; Zee P; Aur RJ; Johnson WW
J Pediatr; 1970 Sep; 77(3):474-83. PubMed ID: 5278225
[No Abstract] [Full Text] [Related]
9. L-asparaginase (NSC-109229) plus azaserine (NSC-742) in acute lymphatic leukemia.
Leventhal BG; Skeel RT; Yankee RA; Henderson ES
Cancer Chemother Rep; 1970 Feb; 54(1):47-51. PubMed ID: 4945997
[No Abstract] [Full Text] [Related]
10. Comparison of crystalline and amorphous asparaginase in treatment of acute leukemia in children.
Pratt CB; Verzosa M
Clin Pharmacol Ther; 1972; 13(3):343-8. PubMed ID: 4554659
[No Abstract] [Full Text] [Related]
11. Low-dosage asparaginase treatment of childhood acute lymphocytic leukemia.
Pratt CB; Choi SI; Holton CP
Am J Dis Child; 1971 May; 121(5):406-9. PubMed ID: 5283023
[No Abstract] [Full Text] [Related]
12. L-Asparaginase: human toxicology and single agent activity in nonleukemic neoplasms.
Haskell CM
Cancer Treat Rep; 1981; 65 Suppl 4():57-9. PubMed ID: 7049381
[TBL] [Abstract][Full Text] [Related]
13. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma.
Evans WE; Tsiatis A; Rivera G; Murphy SB; Dahl GV; Denison M; Crom WR; Barker LF; Mauer AM
Cancer; 1982 Apr; 49(7):1378-83. PubMed ID: 7037164
[TBL] [Abstract][Full Text] [Related]
14. Acute pancreatitis in children with acute lymphoblastic leukemia treated with L-asparaginase.
Flores-Calderón J; Exiga-Gonzaléz E; Morán-Villota S; Martín-Trejo J; Yamamoto-Nagano A
J Pediatr Hematol Oncol; 2009 Oct; 31(10):790-3. PubMed ID: 19770681
[TBL] [Abstract][Full Text] [Related]
15. [Asparaginase, leukemia and cancer].
Levy D; Boiron M
Bull Cancer; 1969; 56(4):365-74. PubMed ID: 4928248
[No Abstract] [Full Text] [Related]
16. The clinical toxicities of L-asparaginase in treatment of leukemia and lymphoma.
Zubrod CG
Pediatrics; 1970 Apr; 45(4):555-9. PubMed ID: 5438160
[No Abstract] [Full Text] [Related]
17. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
18. Favorable remission induction rate with twice weekly doses of L-asparaginase.
Jaffe N; Traggis D; Das L; Frauenberger G; Hann HW; Kim BS; Bishop Y
Cancer Res; 1973 Jan; 33(1):1-4. PubMed ID: 4565907
[No Abstract] [Full Text] [Related]
19. L-asparaginase activity in plasma and other biological fluids.
Schwartz MK; Lash ED; Oettgen HF; Tomato FA
Cancer; 1970 Feb; 25(2):244-52. PubMed ID: 4905152
[No Abstract] [Full Text] [Related]
20. [Experimenting with the use of L-asparaginase in the treatment of neoplasms of the blood system].
Lorie IuI; Kruglova GV; Poddubnaia IV; Mansurov AN
Klin Med (Mosk); 1973 Jun; 51(6):52-8. PubMed ID: 4774561
[No Abstract] [Full Text] [Related]
[Next] [New Search]
